CG
SGMT icon

Column Group’s Sagimet Biosciences SGMT Stock Holding History

Column Group’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17,169
Closed -$47.6K – 6
2024
Q3 		$47.6K Hold
17,169
– – 0.07% 5
2024
Q2 		$58.7K Hold
17,169
– – 0.08% 5
2024
Q1 		$93.1K Buy
+17,169
New +$123K 0.06% 6

Other funds holding SGMT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Column Group's SGMT Position: Q4 2024 in Review

Column Group sold out of Sagimet Biosciences (SGMT) in Q4 2024, closing a stake of 17,169 shares — an estimated $47.6K sold.

Column Group first reported a position in SGMT in Q1 2024 and held it in 3 quarters. The position peaked at $93.1K in Q1 2024. 66 funds tracked by Wall St. Rank hold SGMT as of Q4 2024.

  • Column Group reported no remaining Sagimet Biosciences position as of Q4 2024 after selling out during the quarter.
  • Column Group sold 17,169 Sagimet Biosciences shares in Q4 2024, an estimated $47.6K.
  • Column Group first reported a position in Sagimet Biosciences in Q1 2024 and held it in 3 quarters.
  • Column Group's Sagimet Biosciences position peaked at $93.1K in Q1 2024.
  • 66 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q4 2024.

Based on Column Group's 13F filing for Q4 2024, filed 14 Feb 2025.